Supplementary Table S6—Adverse events observed during veterinary examinations conducted weekly over 4 weeks of dosing for the dogs of Table S1.*

Category	AE	Weeks observed	Placebo		1 mg/kg		2 mg/kg		4 mg/kg		12 mg/kg	
			AEs (n)	dogs (n)	AEs (n)	dogs (n)	AEs (n)	dogs (n)	AEs (n)	dogs (n)	AEs (n)	dogs (n)
Ocular	Conjunctivitis	1, 3, 4	2†	2†	1	1	2	2	2	2	2	1
Immunological	Palpable lymph nodes‡	1, 2, 3, 4	4	3	3	2	2	2	1	1	2	1
Cardiac	Tachycardia (>140 bpm)	3	-	-	1	1	-	-	-	-	-	-
	Arrhythmia	3	-	-	-	-	-	-	-	-	1	1
Otic	Cerumen	2, 4	1	1	-	-	-	-	-	-	3	2
	Inflamed ear	3	1	1	-	-	-	-	-	-	-	-
	Induration (pinna)	4	-	-	1	1	-	-	-	-	-	-
Dermatological	Ulceration/wound/clipper burn	1, 3, 4	1	1	-	-	1	1	-	-	1	1
	Excoriation	3, 4	1	1	-	-	1	1	-	-	-	-
	Alopecia	4	-	-	1	1	-	-	-	-	-	-
	Hygroma	2	-	-	-	-	-	-	-	-	1	1
Musculoskeletal	Kink distal tail	2, 4	-	-	-	-	-	-	1	1	1	1
	Inguinal hernia	4	-	-	-	-	-	-	-	-	1	1
Gastrointestinal	Flatulence	1, 2, 4	1	1	-	-	4	3	2	1	2	2

n, number

*Veterinary examinations occurred during acclimation, baseline (one day prior to treatment start), and weekly over the four-week dosing period. The above table summarizes AEs that were observed during the four-week dosing period that were not also observed at baseline.

† Indicates two observations of conjunctivitis across two dogs (one observation in each of two dogs) over four weeks of dosing.

‡ Palpable lymph nodes were popliteal, prescapular, or sublingual. In only one case, in one dog (placebo group, Week 2), was a lymph node ‘slightly enlarged’.